151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)
Titel:
151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)
Auteur:
Xue, Q. Wang, B. Wang, X. Ding, X. Liu, Y. Wang, X. Liu, N. Zhan, H. Ke, B. Li, B. Cai, M. Deng, J. Wu, L. Huang, W. Liu, H. Sun, Y. Liang, H.